E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neovascular ("wet") Age-related Macular Degeneration (NV- AMD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064930 |
E.1.2 | Term | Age-related macular degeneration |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objectives of this study are to establish the safety of ATG003 and to determine preliminary efficacy of two doses of ATG003 compared to placebo. The primary objective is to compare the change in visual acuity from baseline to week 48 between the patients treated with ATG003 to those treated with placebo - the proportion of patients losing fewer than 15 ETDRS letters (3 lines) of visual acuity in the study eye, using a standardized refraction and testing protocol at a starting test distance of 4 meters. |
|
E.2.2 | Secondary objectives of the trial |
To confirm the safety of ATG003 when given as twice daily eye drops for 48 weeks: proportion of patients losing fewer than 15 ETDRS letters of visual acuity in the study eye at 24 weeks compared to baseline; time to a loss of 15 ETDRS letters; mean change in VA over time from baseline; proportion of patients gaining 15 or more letters; the time to a gain of 15 ETDRS letters of VA in the study eye; proportion of patients with a Snellen equivalent of 20/200 or worse. Other secondary objectives include measures of anatomical changes to the retina: proportion of patients that have stable or reduced CNV lesion size; proportion of patients that have a 30% reduction in excess foveal thickness and/or subretinal fluid by OCT; mean and median change in excess foveal thickness and/or subfoveal fluid by OCT
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Be males or females aged 50 years or older. Have subfoveal choroidal neovascularization (CNV) secondary to AMD of any angiographic subtype (classic, minimally classic, or occult with no classic). Have active CNV (which can include both classic and occult component) in the study eye which comprises at least 50% of the total area of the lesion (including blood,atrophy and scar). Have center point retinal thickness as measured by OCT of at least 275 microns due to subretinal and/or intraretinal fluid in the study eye Have best-corrected visual acuity using ETDRS charts of 20/40 to 20/400 (Snellen equivalent) in the study eye. Provide written informed consent Be able to comply with all study procedures and return for all study visits.
|
|
E.4 | Principal exclusion criteria |
Scarring or atrophy of the fovea, or comprising > 25% of the total lesion area. Subretinal hemorrhage that involves the fovea, and if the size of the hemorrhage is either 50% or more of the total lesion area, or >1 disc areas in size. Retinal pigment epithelial tear involving the macula. Diabetic Retinopathy. Vitreous hemorrhage. Intraocular pressure of >30 mmHg despite treatment with anti-glaucoma medications Presence of significant ocular abnormalities that prevent retinal assessment, including media opacities (for example, cataract) and inadequate pupillary dilation, Likelihood that they will require cataract surgery in the study eye within the following year. Narrow angle glaucoma, diabetic retinopathy, retinal vascular occlusion, epiretinal membrane, or other conditions that are likely to significantly affect visual acuity during the study period. Presence of other causes of CNV including pathologic myopia (spherical equivalent of 8 diopters or more, or axial length of > 25mm), histoplasmosis syndrome, trauma, angioid streaks, choroidal rupture, or multifocal choroiditis History of any intraocular surgery (including cataract surgery) within 3 months of study entry. The following treatments for AMD within the previous six months including thermal laser, anti-VEGF therapy, intraocular or intravitreal corticosteroids, verteporfin photodynamic therapy, external- beam radiation therapy (in the region of the study eye), transpupillary thermotherapy, or any experimental therapies.Intraocular inflammation or periocular infection. History of allergy to fluorescein, not amenable to treatment with diphenhydramine. History of clinically significant renal disease or significant liver abnormality. Presence of any other concomitant medical condition that would adversely affect the patient’s ability to complete the study, or that might affect interpretation of the results of the study Any treatment with an investigational agent in the past 12 weeks for any condition
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of patients losing fewer than 15 ETDRS letters (3 lines) of visual acuity in the study eye assessed at 48 weeks compared to baseline using a standardized refraction and testing protocol at a starting test distance of 4 meters. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 13 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |